For years the Dutch have been courting Russian business. Now they want their dead back
Traffic to Chipotle Mexican Grill increased in the second quarter, despite price increases
It remains to be seen whether any religious groups with federal contracts will argue that they should be allowed to discriminate if they want to
What Netflix lovingly refers to as "Content" puts the company far ahead of Amazon and Hulu in the race to become a real HBO competitor
A months-long public-relations debacle is taking a heavy toll on the operators of dark pools
The furniture manufacturer of midcentury classics acquires its largest retail outlet
That an accordion-playing parodist has become one of the most enduring musical acts of our time is, well, a little weird
A new report shows young college-educated professionals will wait a long time to see the financial rewards of their degree.
Profiled companies pay the recruiting service, but job-seekers don't
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."